Bengt Winblad

Bengt Winblad

Auto-generated profile, based on publicly available information

Bengt Winblad

Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in The Lancet Neurology
Verified
Journal Article
Closed access
BWBengt Winblad
Bengt Winblad
PAPhilippe Amouyel
Philippe Amouyel
SASandrine Andrieu
Sandrine Andrieu
CBClive Mr. Ballard
Clive Mr. Ballard
CBCarol Brayne
Carol Brayne
HZHenrik Zetterberg
Henrik Zetterberg

2 August 2017 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
HSHiroki Sasaguri
Hiroki Sasaguri
PNPer Nilsson
Per Nilsson
SHShoko Hashimoto
Shoko Hashimoto
KNKenichi Nagata
Kenichi Nagata
TSTakashi Saito
Takashi Saito
TSTakaomi C Saido
Takaomi C Saido
Animal models of human diseases that accurately recapitulate clinical pathology are indispensable for understanding molecular mechanisms and advancing preclinical studies. The Alzheimer's disease (AD) research community has historically used first‐generation transgenic (Tg) mouse models that overexpress proteins linked to familial AD (FAD), mutant amyloid precursor protein (APP), or APP and presenilin (PS). These mice exhibit AD pathology, but the overexpression paradigm may cause additional phenotypes unrelated to AD. Second‐generation mouse models contain humanized sequences and clinical mutations in the endogenous mouse App gene. These mice show Aβ accumulation without phenotypes related to overexpression but are not yet a clinical recapitulation of human AD. In this review, we evaluate different APP mouse models of AD, and review recent studies using the second‐generation mice. We advise AD researchers to consider the comparative strengths and limitations of each model against the scientific and therapeutic goal of a prospective preclinical study.

18 March 2015 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
KJKatrin Jekel
Katrin Jekel
MDMarinella Damian
Marinella Damian
CWCarina Wattmo
Carina Wattmo
LHLucrezia Hausner
Lucrezia Hausner
RBRoger Bullock
Roger Bullock
LFLutz FROELICH
Lutz FROELICH
Introduction: There is a growing body of evidence that subtle deficits in instrumental activities of daily living (IADL) may be present in mild cognitive impairment (MCI). However, it is not clear if there are IADL domains that are consistently affected across patients with MCI. In this systematic review, therefore, we aimed to summarize research results regarding the performance of MCI patients in specific IADL (sub)domains compared with persons who are cognitively normal and/or patients with dementia. Methods: The databases PsycINFO, PubMed and Web of Science were searched for relevant literature in December 2013. Publications from 1999 onward were considered for inclusion. Altogether, 497 articles were retrieved. Reference lists of selected articles were searched for potentially relevant articles. After screening the abstracts of these 497 articles, 37 articles were included in this review. Results: In 35 studies, IADL deficits (such as problems with medication intake, telephone use, keeping appointments, finding things at home and using everyday technology) were documented in patients with MCI. Financial capacity in patients with MCI was affected in the majority of studies. Effect sizes for group differences between patients with MCI and healthy controls were predominantly moderate to large. Performance-based instruments showed slight advantages (in terms of effect sizes) in detecting group differences in IADL functioning between patients with MCI, patients with Alzheimer’s disease and healthy controls. Conclusion: IADL requiring higher neuropsychological functioning seem to be most severely affected in patients with MCI. A reliable identification of such deficits is necessary, as patients with MCI with IADL deficits seem to have a higher risk of converting to dementia than patients with MCI without IADL deficits. The use of assessment tools specifically designed and validated for patients with MCI is therefore strongly recommended. Furthermore, the development of performance-based assessment instruments should be intensified, as they allow a valid and reliable assessment of subtle IADL deficits in MCI, even if a proxy is not available. Another important point to consider when designing new scales is the inclusion of technology-associated IADL. Novel instruments for clinical practice should be time-efficient and easy to administer.

1 July 2008 in American Journal of Public Health
Verified
Journal Article
Open access
AMAlessandra Marengoni
Alessandra Marengoni
BWBengt Winblad
Bengt Winblad
AKAnita Karp
Anita Karp
LFLaura Fratiglioni
Laura Fratiglioni
We explored the role of age, gender, and socioeconomic status in the occurrence of chronic diseases and multimorbidity in 1099 elderly participants in the Kungsholmen Project. Cardiovascular and mental diseases were the most common chronic disorders. Of the participants, 55% had multimorbidity. Advanced age, female gender, and lower education were independently associated with a more than 50% increased risk for multimorbidity. Multimorbidity is the most common clinical picture of the elderly and may be increased by unhealthy behaviors linked to education.

1 April 2006 in The Lancet
Verified
Journal Article
Closed access
BWBengt Winblad
Bengt Winblad
LKLena Kilander
Lena Kilander
SESture Eriksson
Sture Eriksson
LMLennart Minthon
Lennart Minthon
SBStellan Båtsman
Stellan Båtsman
AHAnders Haglund
Anders Haglund

1 July 2012 in The Lancet Neurology
Verified
Journal Article
Closed access
BWBengt Winblad
Bengt Winblad
NANiels Andreasen
Niels Andreasen
LMLennart Minthon
Lennart Minthon
AFAnnette Floesser
Annette Floesser
GIGeorges Imbert
Georges Imbert
AGAna Graf
Ana Graf